Head-to-head comparative effectiveness studies of adults (aged ≥18 years) with IMIDs (including rheumatoid arthritis, inflammatory bowel disease, psoriasis or psoriatic arthritis, or spondyloarthropathy) treated with either JAK inhibitors or TNF antagonists were included. This evidence concerns the gene TNF and rheumatoid arthritis.